보고서 요약(국문)

개요
전 세계 베체트병 시장은 2022년 XX백만 달러에 달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) XX%로 성장하여 2030년에는 XX백만 달러에 이를 것으로 예상됩니다.
실크로드병이라고도 불리는 베체트병은 혈관염(혈관의 염증)으로 인해 발생하는 만성 염증성 질환입니다. 동맥과 정맥에 손상을 줄 수 있으며, 개인마다 다양한 증상이 나타날 수 있습니다. 재발성 구내염, 질 궤양, 눈 염증은 베체트병의 전형적인 증상입니다.
이 외에도 위장 문제, 관절 통증 및 부종, 피부 궤양 등이 나타날 수 있습니다. 베체트병은 아직 완치할 수 없지만, 염증을 줄이고 면역 체계를 조절하는 약물을 사용하여 증상을 관리할 수 있습니다. 환자의 증상에 따라 코르티코스테로이드, 면역억제제, 통증 및 기타 특정 증상 치료제 등이 치료 과정에 사용될 수 있습니다.
시장 동향: 성장 동인 및 제약 요인
기업들이 채택한 전략
현재 만성적이고 고통스러운 질환인 베체트병에 대한 완치법은 없습니다. 환자들이 흔히 겪는 증상은 삶의 질에 부정적인 영향을 미칩니다. 이러한 미충족 의료 수요를 해결함으로써 치료법은 환자의 삶의 질을 향상시키고 제약 회사들에게 잠재적인 시장을 창출할 수 있습니다. 따라서 기업들이 채택한 전략은 시장 확장을 가속화하는 데 도움이 됩니다.
예를 들어, 2023년 5월 솔리제닉스(Soligenix, Inc.)는 비상장 회사인 실크로드 테라퓨틱스(Silk Road Therapeutics)와 독점 옵션 계약을 체결했다고 발표했습니다. 이 옵션 계약 조건에 따라 솔리제닉스는 베체트병 환자의 점막 피부 궤양 치료를 위한 비생물학적 항-TNF-알파 억제제인 펜톡시필린(PTX)의 새로운 국소 제형을 구매할 권리를 갖습니다.

정부 프로그램과 베체트병과 같은 희귀 질환 연구 자금 지원은 시장에 큰 영향을 미칠 수 있습니다. 자금 지원, 보조금 및 규제 지원을 통해 신약 개발 속도를 높이고 환자의 치료 접근성을 개선할 수 있습니다.
시장 역학: 제약 요인
베체트병은 여러 가지 제약 요인으로 인해 진단, 치료 및 연구에 어려움을 겪을 수 있습니다. 예를 들어, 증상의 심각도는 사람마다 크게 다릅니다. 어떤 사람은 경미한 증상을 경험하는 반면 다른 사람은 심각한 문제를 겪을 수 있으므로 표준화된 치료 프로토콜을 수립하기 어려울 수 있습니다.
또한, 베체트병의 증상을 완화하는 약물이 있지만, 일부 환자는 기존 치료법에 잘 반응하지 않아 증상 조절을 위한 선택지가 제한될 수 있습니다. 일반 대중, 의료 전문가, 심지어 일부 전문의의 지식 부족으로 인해 진단이 지연되거나 부정확해질 수 있습니다.

베체트병은 진단이 늦어지거나 부정확해질 수 있습니다. 시장 세분화 분석
전 세계 베체트병 시장은 질병 유형, 약물 계열, 유통 채널 및 지역별로 세분화됩니다.
질병 유형 부문 중 PDE4 억제제 부문은 베체트병 시장 점유율의 약 31.7%를 차지했습니다.
PDE4 억제제는 염증 반응에 관여하는 PDE4 효소를 표적으로 하는 약물 계열입니다. 이 억제제는 PDE4의 작용을 억제하여 세포 내 cAMP(cyclic adenosine monophosphate) 수치를 증가시킵니다. PDE4 억제제는 cAMP 수치를 높이고 면역 반응 조절을 돕고 염증을 감소시켜 베체트병과 같은 염증성 질환 치료에 효과적일 가능성이 있습니다.

또한, 미국 베체트병 협회에 따르면, 경구용 선택적 포스포디에스테라제 4(PDE4) 억제제인 아프레밀라스트(오테즐라)는 미국 식품의약국(FDA)에서 베체트병 관련 구강 궤양 치료제로 승인한 최초이자 유일한 약물입니다. 따라서 이러한 요인들이 해당 부문의 성장을 촉진하는 데 기여하고 있습니다.
지역 분석
아시아 태평양 지역은 2022년 시장 점유율의 약 38.4%를 차지했습니다.
베체트병의 유병률 증가 추세는 예측 기간 동안 아시아 태평양 지역의 시장 성장을 견인할 것으로 예상됩니다. 특히 중국과 일본에 거주하는 사람들에게서 흔히 나타나며, 북위 30도에서 45도 사이의 인구에서 자주 관찰됩니다. 예를 들어, 2021년 5월 임상 류마티스 및 면역학 저널(Journal of Clinical Rheumatology and Immunology)에 발표된 연구에 따르면 동아시아에서 베체트병 유병률은 일본 10만 명당 16명, 한국 10만 명당 35명, 중국 10만 명당 14명으로 보고되었습니다. 이러한 정보는 예측 기간 동안 해당 지역의 베체트병 시장 성장을 견인할 것으로 예상됩니다.
또한, 베체트병은 중동, 특히 옛 실크로드 연선 국가들과 지중해 지역(터키, 이란, 이라크, 극동 국가 포함)에서 더 널리 퍼져 있습니다. 실크로드 연선 국가에서는 10만 명당 14~20명의 환자가 발생합니다. 터키는 베체트병 유병률이 가장 높은 국가로, 10만 명당 20~602명이 발병합니다. 따라서 예측 기간 동안 중동 지역이 시장을 주도할 것으로 예상됩니다.

COVID-19 영향 분석
많은 국가에서 팬데믹이 절정에 달했을 때 의료 시스템에 상당한 부담이 가해졌고, 이로 인해 특히 베체트병 환자들의 일상적인 의료 서비스가 차질을 빚었습니다. 진료 예약 불이행이나 취소로 인해 베체트병 치료 및 관리에 차질이 생겼을 수 있습니다. 또한, 팬데믹으로 인해 베체트병 관련 임상 시험 및 연구가 연기되거나 중단되었을 가능성도 있습니다.
이는 새로운 치료제 및 치료법 개발에 영향을 미칠 수 있습니다. 특히 면역억제 치료를 받고 있는 베체트병 환자들은 COVID-19에 감염될 경우 중증으로 발전할 가능성에 대한 불안감을 더욱 크게 느꼈을 수 있습니다. 이러한 불안감은 환자들이 의료 시스템을 이용하는 방식이나 치료 관련 결정에 영향을 미쳤을 수 있습니다.

시장 세분화
질병 유형별
• 신경 베체트병
• 안구 베체트병
• 혈관 베체트병
약물 종류별
• 코르티코스테로이드
• 포스포디에스테라제 4 억제제
• 면역억제제
• 통풍 치료제
• 국소 치료제
• 기타
유통 채널별
• 병원 약국
• 온라인 약국
• 소매 약국
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 스페인
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
경쟁 환경
시장의 주요 글로벌 업체로는 Par Pharmaceutical, Takeda Pharmaceuticals U.S.A., Inc, Endo International plc, Pfizer 등이 있습니다. 주요 기업으로는 Sebela Pharmaceuticals, Aark Pharmaceuticals, Janssen Pharmaceuticals, Genentech, Inc, Amgen Inc, Delphis Pharmaceutical 등이 있습니다.

보고서 구매 이유:

• 질병 유형, 약물 종류, 유통 채널 및 지역별 글로벌 베체트병 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 베체트병 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석을 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품을 포함한 제품 맵핑 Excel 파일을 제공합니다.

글로벌 베체트병 시장 보고서는 약 69개의 표, 58개의 그림, 187페이지로 구성됩니다.
2023년 주요 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
Global Behcet’s Disease Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.
Behcet's disease, also known as Silk Road disease, is an inflammatory disease that lasts a long time and can be brought on by vasculitis (inflammation of the blood vessels). It can harm the arteries and veins. A wide range of symptoms that differ from person to person might result from this illness. Recurrent mouth ulcers, vaginal ulcers, and eye inflammation are typical signs of behcet’s disease.
It can also result in gastrointestinal issues, joint discomfort and swelling, and skin sores in addition to these symptoms. Behcet’s disease has no known cure, but its symptoms can be controlled using drugs that lessen inflammation and regulate the immune system. Corticosteroids, immunosuppressive drugs, and medications to treat pain and other particular symptoms may all be used in the process of treatment depending on the patient's symptoms.
Market Dynamics: Drivers and Restraints
The strategies adopted by the companies
There is currently no cure for the chronic, painful disease known as behcet’s disease. Symptoms that patients frequently experience negatively affect their quality of life. By addressing this unmet medical need, therapies can improve patients' lives while setting up a potential market for pharmaceutical companies. Thus, the companies strategies employed aid to accelerate market expansion.
For instance, in May 2023, Soligenix, Inc. reported that it had signed an exclusive option contract with privately held Silk Road Therapeutics. In accordance with the terms of the option agreement, the Company is entitled to purchase a novel topical formulation of Pentoxifylline (PTX), a non-biological anti-TNF-alpha inhibitor, for the treatment of mucocutaneous ulcers in behcet’s disease patients.
Government programmes and funding for research on uncommon illnesses, such as behcet’s disease, can also have a big impact on the market. Drug development can be speed up and patient access to therapies can be improved with funding, grants, and regulatory support.
Market Dynamics: Restraint
Behcet’s disease may be constrained by a number of circumstances, making diagnosis, treatment, and research efforts challenging. For instance, the severity of the symptoms varies greatly from person to person. It might be challenging to establish standardised treatment protocols because some people may experience modest symptoms while others may suffer from serious problems.
Additionally, while there are medications to address the symptoms, for behcet’s disease. Some people might not respond well to the therapies that are available, leaving them with few options for symptom control. Lack of knowledge among the general population, medical professionals, and even some specialists may lead to a delayed or inaccurate diagnosis.
Segment Analysis
The global behcet’s disease marketis segmented based on disease type, drug class, distribution channel and region.
The PDE4 inhibitors segment from the type segment accounted for approximately 31.7% of behcet’s disease share
PDE4 inhibitors are a class of drugs that focus on the PDE4 enzyme, which is involved in the inflammatory response. These inhibitors function by preventing PDE4 from doing its task, which raises intracellular cyclic adenosine monophosphate (cAMP) levels. PDE4 inhibitors have the potential to be effective in the treatment of inflammatory illnesses, such as behcet’s disease, by enhancing cAMP levels and assisting in the regulation of the immune response and decreasing inflammation.
Moreover, according to American Behcet's Disease Association, stated that, apremilast (Otezla), an oral selective phosphodiesterase 4 (PDE4) inhibitor, is the first and only approved treatment by the US Food and Drug Administration (FDA) for oral ulcers associated with Behcet's Disease. Thus above factors helps to boost the segment growth.
Geographical Analysis
Asia Pacific accounted for approximately 38.4% of the market share in 2022
The rising prevalence of behcet's disease is expected to lead to favorable market expansion in the Asia Pacific region during the forecast period. It is frequently seen by those who live in China and Japan. Between the populations of the 30th and 45th degree latitudes, it is regularly observed. For instance, a research study published in May 2021 in the Journal of Clinical Rheumatology and Immunology reported that in East Asia, the prevalence was reported to be 16/100,000 in Japan, 35/100,000 in Korea, and 14/100,000 in China. This knowledge is expected to drive the behcet's disease market growth during the forecast period in the region.
Additionally, behcet’s disease is more widespread in the Middle East, particularly in the nations along the old Silk Road and in the Mediterranean region, where it is also common, including Turkey, Iran, Iraq, and countries in the Far East. There are 14–20 cases of the illness for every 100,000 people along the Silk Road. Turkey has the highest prevalence of BD, with 20-602/100,000. Thus, it is expected that the Middle East will dominate the market over the forecast period.
COVID-19 Impact Analysis
Healthcare systems were under pressure during the pandemic's peak in numerous countries, which disrupted routine medical care, particularly for those with behcet’s disease. The care and treatment of the condition may have been compromised by missed or cancelled appointments. The pandemic may have caused certain clinical trials and research studies on Behçet's illness to be postponed or discontinued.
This might have an effect on the creation of novel illness medicines and treatments. Patients with behcet’s disease, especially that on immunosuppressive therapy, could have had to deal with more worries about their propensity for developing a serious illness in the event that they got COVID-19. Their contacts with the healthcare system and decisions about their care may have been affected by these concerns.
Market Segmentation
By Disease Type
• Neuro-Behcet
• Ocular-Behcet
• Vasculo-Behcet
By Drug Class
• Corticosteroids
• Phosphodiesterase 4 Inhibitor
• Immunosuppressive Drugs
• Anti-gout Agents
• Topical Treatments
• Others
By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Spain
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Competitive Landscape
The major global players in the market include Par Pharmaceutical, Takeda Pharmaceuticals U.S.A., Inc, Endo International plc, Pfizer Inc, Sebela Pharmaceuticals, Aark Pharmaceuticals, Janssen Pharmaceuticals, Genentech, Inc, Amgen Inc, Delphis Pharmaceutical and among others.
Why Purchase the Report?
• To visualize the global behcet’s disease market segmentation based on disease type, drug class, distribution channel and region as well as understandkey commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of behcet’s disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global behcet’s disease market report would provide approximately 69 tables, 58 figures and 187 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Drug Class
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Market Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The strategies adopted by the companies
4.1.1.2. The rising prevalence of disease
4.2. Restraints
4.2.1.1. The symptoms and their severity can vary widely from person to person
4.2.2. Opportunity
4.2.3. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Pipeline Analysis
5.6. Unmet Needs
5.7. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Neuro-Behcet *
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Ocular-Behcet
7.4. Vasculo-Behcet
8. By Drug Class
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
8.1.2. Market Attractiveness Index, By Drug Class
8.2. Corticosteroids *
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Phosphodiesterase 4 Inhibitor
8.4. Immunosuppressive Drugs
8.5. Anti-gout Agents
8.6. Topical Treatments
8.7. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Online Pharmacies
9.4. Retail Pharmacies
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Par Pharmaceutical *
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Takeda Pharmaceuticals U.S.A., Inc
12.3. Endo International plc
12.4. Pfizer Inc
12.5. Sebela Pharmaceuticals
12.6. Aark Pharmaceuticals
12.7. Janssen Pharmaceuticals
12.8. Genentech, Inc
12.9. Amgen Inc
12.10. Delphis Pharmaceutical
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Par Pharmaceutical, 4.	Key Developments, Takeda Pharmaceuticals U.S.A., Inc, Endo International plc, Pfizer Inc, Sebela Pharmaceuticals, Aark Pharmaceuticals, Janssen Pharmaceuticals, Genentech, Inc, Amgen Inc, Delphis Pharmaceutical

표 목록 (Tables)

List of Tables

Table 1 Global Behçet’s Disease Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 2 Global Behçet’s Disease Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 3 Global Behçet’s Disease Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 4 Global Behçet’s Disease Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 5 Global Behçet’s Disease Market Value, By Disease Type, 2023, 2027 & 2031 (US$ Million)

Table 6 Global Behçet’s Disease Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 7 Global Behçet’s Disease Market Value, By Drug Class, 2023, 2027 & 2031 (US$ Million)

Table 8 Global Behçet’s Disease Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 9 Global Behçet’s Disease Market Value, By Distribution Channel, 2023, 2027 & 2031 (US$ Million)

Table 10 Global Behçet’s Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 11 Global Behçet’s Disease Market Value, By Region, 2023, 2027 & 2031 (US$ Million)

Table 12 Global Behçet’s Disease Market Value, By Region, 2022-2031 (US$ Million)

Table 13 North America Behçet’s Disease Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 14 North America Behçet’s Disease Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 15 North America Behçet’s Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 16 North America Behçet’s Disease Market Value, By Country, 2022-2031 (US$ Million)

Table 17 South America Behçet’s Disease Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 18 South America Behçet’s Disease Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 19 South America Behçet’s Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 20 South America Behçet’s Disease Market Value, By Country, 2022-2031 (US$ Million)

Table 21 Europe Behçet’s Disease Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 22 Europe Behçet’s Disease Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 23 Europe Behçet’s Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 24 Europe Behçet’s Disease Market Value, By Country, 2022-2031 (US$ Million)

Table 25 Asia-Pacific Behçet’s Disease Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 26 Asia-Pacific Behçet’s Disease Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 27 Asia-Pacific Behçet’s Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 28 Asia-Pacific Behçet’s Disease Market Value, By Country, 2022-2031 (US$ Million)

Table 29 Middle East & Africa Behçet’s Disease Market Value, By Disease Type, 2022-2031 (US$ Million)

Table 30 Middle East & Africa Behçet’s Disease Market Value, By Drug Class, 2022-2031 (US$ Million)

Table 31 Middle East & Africa Behçet’s Disease Market Value, By Distribution Channel, 2022-2031 (US$ Million)

Table 32 Par Pharmaceutical: Overview

Table 33 Par Pharmaceutical: Product Portfolio

Table 34 Par Pharmaceutical: Key Developments

Table 35 Takeda Pharmaceuticals U.S.A., Inc: Overview

Table 36 Takeda Pharmaceuticals U.S.A., Inc: Product Portfolio

Table 37 Takeda Pharmaceuticals U.S.A., Inc: Key Developments

Table 38 Endo International plc: Overview

Table 39 Endo International plc: Product Portfolio

Table 40 Endo International plc: Key Developments

Table 41 Pfizer Inc: Overview

Table 42 Pfizer Inc: Product Portfolio

Table 43 Pfizer Inc: Key Developments

Table 44 Sebela Pharmaceuticals: Overview

Table 45 Sebela Pharmaceuticals: Product Portfolio

Table 46 Sebela Pharmaceuticals: Key Developments

Table 47 Aark Pharmaceuticals: Overview

Table 48 Aark Pharmaceuticals: Product Portfolio

Table 49 Aark Pharmaceuticals: Key Developments

Table 50 Janssen Pharmaceuticals: Overview

Table 51 Janssen Pharmaceuticals: Product Portfolio

Table 52 Janssen Pharmaceuticals: Key Developments

Table 53 Genentech, Inc: Overview

Table 54 Genentech, Inc: Product Portfolio

Table 55 Genentech, Inc: Key Developments

Table 56 Amgen Inc: Overview

Table 57 Amgen Inc: Product Portfolio

Table 58 Amgen Inc: Key Developments

Table 59 Delphis Pharmaceutical: Overview

Table 60 Delphis Pharmaceutical: Product Portfolio

Table 61 Delphis Pharmaceutical: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 2 Global Behçet’s Disease Market Share, By Disease Type, 2023 & 2031 (%)

Figure 3 Global Behçet’s Disease Market Share, By Drug Class, 2023 & 2031 (%)

Figure 4 Global Behçet’s Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 5 Global Behçet’s Disease Market Share, By Region, 2023 & 2031 (%)

Figure 6 Global Behçet’s Disease Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 7 Neuro-Behcet Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 8 Ocular-Behcet Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 9 Vasculo-Behcet Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 10 Global Behçet’s Disease Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 11 Corticosteroids Drug Class in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 12 Phosphodiesterase 4 Inhibitor Drug Class in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 13 Immunosuppressive Drugs Drug Class in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 14 Anti-gout Agents Drug Class in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 15 Topical Treatments Drug Class in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 16 Others Drug Class in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 17 Global Behçet’s Disease Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 18 Hospital Pharmacies Distribution Channel in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 19 Retail Pharmacies Distribution Channel in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 20 Online Stores Distribution Channel in Global Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 21 Global Behçet’s Disease Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 22 North America Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 23 Asia-Pacific Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 24 Europe Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 25 South America Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 26 Middle East and Africa Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 27 North America Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 28 North America Behçet’s Disease Market Share, By Disease Type, 2023 & 2031 (%)

Figure 29 North America Behçet’s Disease Market Share, By Drug Class, 2023 & 2031 (%)

Figure 30 North America Behçet’s Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 31 North America Behçet’s Disease Market Share, By Country, 2023 & 2031 (%)

Figure 32 South America Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 33 South America Behçet’s Disease Market Share, By Disease Type, 2023 & 2031 (%)

Figure 34 South America Behçet’s Disease Market Share, By Drug Class, 2023 & 2031 (%)

Figure 35 South America Behçet’s Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 36 South America Behçet’s Disease Market Share, By Country, 2023 & 2031 (%)

Figure 37 Europe Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 38 Europe Behçet’s Disease Market Share, By Disease Type, 2023 & 2031 (%)

Figure 39 Europe Behçet’s Disease Market Share, By Drug Class, 2023 & 2031 (%)

Figure 40 Europe Behçet’s Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 41 Europe Behçet’s Disease Market Share, By Country, 2023 & 2031 (%)

Figure 42 Asia-Pacific Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 43 Asia-Pacific Behçet’s Disease Market Share, By Disease Type, 2023 & 2031 (%)

Figure 44 Asia-Pacific Behçet’s Disease Market Share, By Drug Class, 2023 & 2031 (%)

Figure 45 Asia-Pacific Behçet’s Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 46 Asia-Pacific Behçet’s Disease Market Share, By Country, 2023 & 2031 (%)

Figure 47 Middle East & Africa Behçet’s Disease Market Value, 2022-2031 (US$ Million)

Figure 48 Middle East & Africa Behçet’s Disease Market Share, By Disease Type, 2023 & 2031 (%)

Figure 49 Middle East & Africa Behçet’s Disease Market Share, By Drug Class, 2023 & 2031 (%)

Figure 50 Middle East & Africa Behçet’s Disease Market Share, By Distribution Channel, 2023 & 2031 (%)

Figure 51 Par Pharmaceutical: Financials

Figure 52 Takeda Pharmaceuticals U.S.A., Inc: Financials

Figure 53 Endo International plc: Financials

Figure 54 Pfizer Inc: Financials

Figure 55 Sebela Pharmaceuticals: Financials

Figure 56 Aark Pharmaceuticals: Financials

Figure 57 Janssen Pharmaceuticals: Financials

Figure 58 Genentech, Inc: Financials

Figure 59 Amgen Inc: Financials

Figure 60 Delphis Pharmaceutical: Financials

세계 베체트병 시장 – 2023-2030

Global Behcet’s Disease Market - 2023-2030